Login to Your Account



Possible M&A Target?

InterMune Skyrockets on CHMP Thumbs-up for IPF Drug Esbriet

By Jennifer Boggs


Monday, December 20, 2010
Shares of InterMune Inc. shot up a whopping 144.5 percent Friday on a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for idiopathic pulmonary fibrosis (IPF) drug pirfenidone, a decision that came about two months earlier than expected and positions the company for a European approval in early 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription